Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00169741 · ClinicalTrials.gov registry record · NA
Renogram Study With Percutaneous Nephrolithotomy (PERC): Alterations in Renal Blood Flow as a Consequence of PERC
A NA study, sponsored by Indiana Kidney Stone Institute.
- Completed
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT00169741 is a NA study that has completed, run by Indiana Kidney Stone Institute. The registered enrollment target is 4 participants.
The verdict
NCT00169741, a NA study, has completed, sponsored by Indiana Kidney Stone Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
Patients with large or otherwise complex renal calculi are commonly treated by percutaneous nephrolithotomy (PNL; PERC). PERC requires the creation of an approximately 10 mm channel through the renal parenchyma, into the intra-renal collecting system, in order to effect stone fragmentation and extraction. Although the nephrostomy tract is confined to a small fraction of the renal parenchyma (approximately 1%), the trauma associated with the creation of the tract will affect blood flow and oxygen delivery to regions beyond the immediate site of injury. It is possible that this could result in a significant functional renal impairment. There are several reports describing the effect of PERC on renal function, but interpretation of these studies is difficult, due to a lack of uniformity in patient selection and variability in the timing of peri-operative evaluation. Recent data from the investigators' lab, obtained from a porcine model, suggest that, acutely, PERC causes a significant decrease in renal function as measured by para amino hippurate (PAH) clearance. The purpose of this study is to determine, in a rigorous and standardized fashion, the acute effects of PERC on renal function, as measured by nuclear renography.
Interventions
- OTHER Renogram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2005-05 |
| Est. Completion | 2016-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00169741
The ClinicalTrials.gov registry entry for NCT00169741 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana Kidney Stone Institute, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Renogram is the first listed.
NCT00169741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00169741 about?
NCT00169741 is a clinical study titled "Renogram Study With Percutaneous Nephrolithotomy (PERC): Alterations in Renal Blood Flow as a Consequence of PERC". Patients with large or otherwise complex renal calculi are commonly treated by percutaneous nephrolithotomy (PNL; PERC). PERC requires the creation of an approximately 10 mm channel through the renal parenchyma, into the intra-renal collecting system, in order to effect stone fragmentation and extra...
What is the current status of trial NCT00169741?
This trial is currently completed. It is a NA study. The enrollment target is 4 participants. The study started on 2005-05. Estimated completion is 2016-02.
What interventions are being tested in trial NCT00169741?
The interventions under investigation include: Renogram (OTHER).
Who is sponsoring clinical trial NCT00169741?
This trial is sponsored by Indiana Kidney Stone Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.